| Market Cap | 615.23K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.65M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 242.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | - | Quick Ratio | 0.19 | Shares Outstanding | 47.33M | 52W Low Chg | 129,900.00% |
| Insider Own | - | ROA | -732.51% | Shares Float | 6.15M | Beta | 628.62 |
| Inst Own | 0.23% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.01 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 5,429 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 10,500 | Change | 0.00% |
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.